# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Irène Joliot-Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB003-SYN-TD
- Date: 1955-09-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Solène Marchand-Ellis, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-day review, seen the same morning by hematology for a bone marrow biopsy. **S**

## History of present illness

Mrs. Joliot-Curie returns two days after her first visit and was seen this morning by Dr. Engquist-Mensah of hematology/oncology, who performed a bone marrow aspiration and biopsy. She feels more tired than two days ago and is breathless on one flight of stairs. Her gums still ooze when she brushes, and two new bruises have appeared on her thighs. She has had no fever, chills, nosebleeds, blood in the urine or stool, headache, or confusion. She has avoided aspirin as advised. She has written down her history of radiation work and the laboratory accident, and has begun asking her employer's radiation safety office for her dose records. **S**

| Element | Detail |
|---|---|
| Symptoms | More tired; breathless on one flight; gum oozing; new bruises; no fever |
| Weight | 53.8 kg |
| Testing today | Bone marrow aspiration and biopsy with flow cytometry, cytogenetics and molecular panel; blood count; INR and fibrinogen; hepatitis B, hepatitis C and HIV tests; HLA typing; chest X-ray |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever, chills or night sweats |
| Respiratory | Positive | Breathless on one flight of stairs; no cough |
| Ears, nose, mouth, and throat | Positive | Gum oozing; no nosebleeds |
| Integumentary | Positive | New bruises on both thighs |
| Neurological | Negative | No headache, visual change or confusion |

5 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/68 mmHg; pulse 100 bpm; respirations 18/min; temperature 37.3 °C; oxygen saturation 97% on room air; weight 53.8 kg; BMI 20.2 kg/m². All vital signs are synthetic.

White cell count: 1.9 10*3/uL (low); Absolute neutrophil count: 0.5 10*3/uL (low); Hemoglobin: 7.1 g/dL (low); Platelets: 22 10*3/uL (low); Blood blasts (smear): 14% (high); Bone marrow blasts: 34% (high); INR: 1.1; Fibrinogen: 310 mg/dL. All results are synthetic.

## Change since baseline

- White cell count: 2.1 10*3/uL (low) at baseline, 1.9 10*3/uL (low) at this visit **S**
- Absolute neutrophil count: 0.6 10*3/uL (low) at baseline, 0.5 10*3/uL (low) at this visit **S**
- Hemoglobin: 8.4 g/dL (low) at baseline, 7.1 g/dL (low) at this visit **S**
- Platelets: 38 10*3/uL (low) at baseline, 22 10*3/uL (low) at this visit **S**
- Blood blasts (smear): 12% (high) at baseline, 14% (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Pale and tired but alert; weight 53.8 kg; pulse 100 |
| Skin | Several bruises on the thighs and shins; petechiae on the lower legs |
| Mouth | Gum petechiae; no gum swelling |
| Lymph nodes | None enlarged |
| Abdomen | No enlarged liver or spleen |
| Bone marrow site | Right posterior iliac crest dressing dry |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Acute myeloid leukemia** (C92.00). The marrow aspirate shows 34 percent myeloblasts with dysplasia in the red cell and platelet lines, and flow cytometry shows myeloid blasts (CD34, CD117, CD13, CD33, HLA-DR and MPO positive): acute myeloid leukemia. Normal INR and fibrinogen, the blast phenotype, and a negative rapid PML::RARA test exclude acute promyelocytic leukemia. Cytogenetics and the molecular panel will take about ten days; classification, risk and the treatment choice depend on them. Dr. Engquist-Mensah and I agree. **S**
   - Cytogenetics and molecular panel from the marrow; review when back.
   - Echocardiogram, ECG, and lung function tests with diffusing capacity on the day of the results review, given her past tuberculosis.
   - HLA typing sent.
   - Hepatitis B, hepatitis C and HIV tests sent before therapy.
2. **Past pulmonary tuberculosis** (Z86.11). Chest X-ray today shows old fibrotic scarring at the right apex and no sign of active disease; she completed treatment. Treated tuberculosis does not need preventive therapy, but reactivation is possible during neutropenia, so a new cough, fever or night sweats will be investigated promptly. **S**
   - Lung function tests with diffusing capacity before treatment.
3. **Occupational exposure to ionizing radiation** (Z57.1). Her account is recorded in full; leukemia after long exposure to ionizing radiation is well recognized. The dose records will show the extent of her monitored exposure. **S**
   - Written request for dosimetry and bioassay records to the employer's radiation safety office, as the regulations entitle her.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with differential and smear | At diagnosis; two to three times a week during induction; before each cycle | Completed today | White cells 1.9, neutrophils 0.5, hemoglobin 7.1 g/dL, platelets 22 x10^3/uL, blasts 14% on the smear |
| Laboratory | Bone marrow: morphology, flow cytometry, cytogenetics, molecular panel | At diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning require | Completed today | Aspirate 34% myeloblasts with multilineage dysplasia; flow cytometry myeloid; cytogenetics and molecular panel sent |
| Laboratory | Coagulation tests (INR, fibrinogen) to exclude the coagulopathy of acute promyelocytic leukemia | At diagnosis | Completed today | INR 1.1, fibrinogen 310 mg/dL: no coagulopathy; rapid PML::RARA negative |
| Laboratory | Chemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver tests | At diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycle | Up to date | Normal kidney and liver tests two days ago; LDH 412 U/L and uric acid 6.4 mg/dL; repeat on the first treatment day |
| Examination | Fitness: performance status, comorbidity (HCT-CI), echocardiogram, lung function | Before choosing induction | Ordered | ECOG 1 two days ago; echocardiogram, ECG and lung function tests booked for the results review |
| Medication safety | Transfusion support: thresholds, irradiated and leukoreduced products | At each blood count | Completed today | Hemoglobin 7.1 g/dL with breathlessness: one unit of irradiated, leukoreduced red cells today; platelets 22 without serious bleeding: no transfusion, as the biopsy is safe at this count |
| Self-management | Infection prophylaxis and the fever plan | From diagnosis | Completed today | Fever plan given in writing: 38.0 °C or more means the emergency department at once; thermometer at home |
| Laboratory | Hepatitis B, hepatitis C and HIV testing before therapy | Once, before therapy | Completed today | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV test sent |
| Referral | HLA typing and allogeneic transplant evaluation | At diagnosis for any patient who may be a transplant candidate | Completed today | HLA typing sent |
| Self-management | Occupational exposure history and dose records | At diagnosis | Completed today | History documented; written request for records begun |

## Goal progress

- Diagnosis, classification and a treatment decision within two weeks of the first visit. In progress; target 1955-09-28. **S**
- Complete cycle 1 without tumor lysis, invasive fungal infection, or bleeding. In progress; target 1955-10-30. **S**
- Remission on the response assessment after cycle 1 (ELN 1951 complete remission, or complete remission with partial hematologic recovery). In progress; target 1955-10-30. **S**
- Her own goals and values recorded and her symptoms controlled with the palliative care team from the first cycle. In progress; target 1955-09-28. **S**
- Her occupational dose records obtained and the exposure history documented. In progress; target 1955-10-30. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026), National Comprehensive Cancer Network
- Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022), European LeukemiaNet (Blood)
- Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022 (PMID 35732831) (2022), World Health Organization (Leukemia)
- Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022 (PMID 35767897) (2022), International Consensus Classification (Blood)
- Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023), Association for the Advancement of Blood and Biotherapies (JAMA)
- Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015), AABB (Annals of Internal Medicine)
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (PMID 32716741) (2020), American Society of Clinical Oncology
- 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026), U.S. Nuclear Regulatory Commission (Electronic Code of Federal Regulations)
- 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026), Occupational Safety and Health Administration

## Follow-up

- Review when the cytogenetics and molecular results are back, in about ten days, with the echocardiogram and lung function tests. Blood count twice weekly with transfusion as needed. Emergency department at once for a temperature of 38.0 °C or more or bleeding that does not stop. **S**
- Next scheduled visit 1955-09-28: genetic results, classification and risk, fitness for treatment, early palliative care, and day 1 of azacitidine with venetoclax. **S**
